Login
$MDGL
$423.96 -$3.43 (0.8%) Live

$MDGL SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
06 Nov 2026 SCHEDULE 13D/A
06 Nov 2026 Form 4: Baker Bros. Advisors Lp, Director and 5 others

Bought 15,666 shares ($5.76M) · Bought 76,140 shares ($29.3M)

06 Nov 2026 Form 4: Kelley Shannon T, General Counsel

Sold 1,077 shares ($431K)

06 Nov 2026 144
03 Nov 2026 10-Q
03 Nov 2026 8-K: Results of Operations and Financial Condition

CONSHOHOCKEN, Pa., Nov. 3, 2026 – Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarte...

28 Sep 2026 144
11 Sep 2026 Form 4: Sibold William John, Director

Sold 6,362 shares ($3.41M) · Sold 5,221 shares ($2.83M)

11 Sep 2026 144
09 Sep 2026 144
20 Aug 2026 Form 4: Kelley Shannon T, General Counsel

Sold 664 shares ($342K)

20 Aug 2026 144
18 Aug 2026 Form 4: Reed John C, Director

Received 647 shares as a grant or award · Granted 1,078 Stock Option (Right to Buy)

18 Aug 2026 Form 3: Reed John C, Director

No securities owned

12 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

CONSHOHOCKEN, Pa., August 12, 2026 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has ...

30 Jul 2026 10-Q
30 Jul 2026 8-K: Results of Operations and Financial Condition

CONSHOHOCKEN, Pa., July 30, 2026 – Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports second-quar...

29 Jul 2026 SCHEDULE 13G/A
20 Jul 2026 Form 4: Sibold William John, Director

Received 50,000 shares by exercise or conversion · Sold 2,500 shares ($1.37M)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support